Clinical Trial Update: SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of the SGN-00101 vaccine for HPV-related cervical cell abnormalities has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Squamous Cells of Undetermined Significance
• Cervical Cancer
• High-grade Squamous Intraepithelial Lesion
• Low-grade Squamous Intraepithelial Lesion

Drugs mentioned

• SGN-00101 Vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Atypical Squamous Cells of Undetermined Significance, Cervical Cancer | Phase 2 | Status: COMPLETED